Horino et al. [18] reported a striking case involving a patient with hepatocellular carcinoma who developed TMA after treatment with atezolizumab, a PD-L1 blocker, and bevacizumab, an inhibitor of VEGF. This evidence concerns the gene CD274 and hepatocellular carcinoma.